Next-gen AAV-delivered anti-GARP/CD3 BiTCE for treatment of hematological and solid tumors
TS-075191 — PROBLEM
Cancer immunotherapies (e.g. ICB, CAR-T cells, and conventional bispecific T cell engagers) have transformed treatment of hematological and solid malignancies; however, their impact is limited by several factors including insufficient durability of therapeutic activity, tumor heterogeneity,…
- College: College of Medicine (COM)
- Inventors: Li, Zihai
- Licensing Officer: He, Panqing
Anti-GARP CAR-T: first-in-class therapy for GARP+ cancers
TS-075163 — THE PROBLEM
High-grade gliomas, including glioblastoma multiforme (GBM), are the most common primary central nervous system tumors with a high recurrence rate and extremely poor overall survival with a 5-year survival rate of approximately 5%. Despite success of CAR-T therapy in treating blood canc…
- College: College of Medicine (COM)
- Inventors: Li, Zihai; Velegraki, Maria
- Licensing Officer: He, Panqing
